87693-29-6

Upstream product

• 109890-19-9 N-<<<4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl>amino>thiooxomethyl>benzamide 

Downstream Products

• 109890-20-2 4,5-dihydro-6-[4-[(4-methyl-2-thiazolyl)amino]phenyl]-3(2H)-pyridazinone 
• 109890-21-3 [1-Amino-1-mercapto-meth-(Z)-ylidene]-methyl-[4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-ammonium; iodide 
• 109890-22-4 6-[4-(1,3-diazacyclopenten-2-ylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone 

Relevant academic research and scientific papers

Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones

Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and the 6-(substituted)phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents.

Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl

The structure-activity relationships of a series of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds were investigated for the in vivo inhibition of different forms of cyclic nucleotide phosphodiesterase (PDE) isolated